Logo image of NXTC

NEXTCURE INC (NXTC) Stock Fundamental Analysis

NASDAQ:NXTC - Nasdaq - US65343E1082 - Common Stock - Currency: USD

0.419  0 (-0.26%)

Fundamental Rating

2

Overall NXTC gets a fundamental rating of 2 out of 10. We evaluated NXTC against 568 industry peers in the Biotechnology industry. NXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NXTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NXTC had negative earnings in the past year.
NXTC had a negative operating cash flow in the past year.
In the past 5 years NXTC always reported negative net income.
In the past 5 years NXTC always reported negative operating cash flow.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of NXTC (-68.83%) is worse than 64.44% of its industry peers.
NXTC has a Return On Equity (-85.00%) which is in line with its industry peers.
Industry RankSector Rank
ROA -68.83%
ROE -85%
ROIC N/A
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

NXTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

6

2. Health

2.1 Basic Checks

NXTC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NXTC has been increased compared to 5 years ago.
There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -7.53, we must say that NXTC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NXTC (-7.53) is worse than 68.13% of its industry peers.
NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.53
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

NXTC has a Current Ratio of 7.50. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
NXTC has a Current ratio of 7.50. This is in the better half of the industry: NXTC outperforms 71.65% of its industry peers.
A Quick Ratio of 7.50 indicates that NXTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.50, NXTC is in the better half of the industry, outperforming 71.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.5
Quick Ratio 7.5
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

NXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.00%, which is quite good.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NXTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.85%
EPS Next 2Y8.91%
EPS Next 3Y13.55%
EPS Next 5Y11.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NXTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NXTC's earnings are expected to grow with 13.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.91%
EPS Next 3Y13.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXTCURE INC

NASDAQ:NXTC (4/24/2025, 8:00:02 PM)

0.419

0 (-0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners48.29%
Inst Owner Change-0.36%
Ins Owners1.81%
Ins Owner Change0%
Market Cap11.74M
Analysts82.5
Price Target3.06 (630.31%)
Short Float %0.27%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.25%
Min EPS beat(2)-19.99%
Max EPS beat(2)-16.51%
EPS beat(4)0
Avg EPS beat(4)-27.4%
Min EPS beat(4)-43.15%
Max EPS beat(4)-16.51%
EPS beat(8)3
Avg EPS beat(8)-9.73%
EPS beat(12)5
Avg EPS beat(12)-6.17%
EPS beat(16)7
Avg EPS beat(16)-3.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.18
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-1.92
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0
BVpS2.34
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.83%
ROE -85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.5
Quick Ratio 7.5
Altman-Z -7.53
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)92.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.15%
EPS Next Y9.85%
EPS Next 2Y8.91%
EPS Next 3Y13.55%
EPS Next 5Y11.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.7%
OCF growth 3YN/A
OCF growth 5YN/A